



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.28
Trade Time:	4:10 PM ET 05/21/18
Change:	-0.10 ↓ (4.202%)
Day Range	2.20 - 2.38
52-Week Range	1.42 - 4.37
Volume	371,058

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 05/15/18
[Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage](#)
- 05/07/18
[Rexahn Reports First Quarter 2018 Financial Results](#)
- 04/26/18
[Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- 03/13/18
[Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)
- 03/12/18
[Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

Financials [\[View all \]](#)

- First Quarter Financial Results
- 03/09/18
[Annual Report \(10-K\)](#)
- 04/23/18
[Proxy Statement \(DEF 14A\)](#)
- 05/04/18
[Quarterly Report \(10-Q\)](#)
- 11/03/17
[Quarterly Report \(10-Q\)](#)
- 08/04/17
[Quarterly Report \(10-Q\)](#)